HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Google Scholar Articles by Lee, S.-W. Articles by Park, S.-J. PubMed Articles by Lee, S.-W. Articles by Park, S.-J. Related Collections Related Article

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients With Diabetes Mellitus

The DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients)

Seung-Whan Lee, MD, PhD^_*, Seong-Wook Park, MD, PhD, FACC^_*,_*, Young-Hak Kim, MD, PhD^_*, Sung-Cheol Yun, PhD^_*, Duk-Woo Park, MD, PhD^_*, Cheol Whan Lee, MD, PhD^_*, Myeong-Ki Hong, MD, PhD^_*, Hyun-Sook Kim, MD, PhD, Jae-Ki Ko, MD, PhD, Jae-Hyeong Park, MD, PhD, Jae-Hwan Lee, MD, Si Wan Choi, MD, In-Whan Seong, MD, PhD, Yoon Haeng Cho, MD, PhD, Nae-Hee Lee, MD, PhD, June Hong Kim, MD, PhD^||, Kook-Jin Chun, MD^|| and Seung-Jung Park, MD, PhD, FACC^_*

^_* Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Chonbuk National University Hospital, Jeonju, Korea
Chungnam National University Hospital, Daejeon, Korea
Soonchunhyang University Bucheon Hospital, Bucheon, Korea
^|| Busan National University Hospital, Busan, Korea.

Manuscript received August 6, 2007; revised manuscript received November 12, 2007, accepted November 13, 2007.

^_* Reprint requests and correspondence: Dr. Seong-Wook Park, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388–1 Poongnap–dong, Songpa-gu, Seoul, 138-736, Korea. (Email: swpark{at}amc.seoul.kr).

Objectives: We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM).

Background: Although cilostazol has reduced the extent of neointimal hyperplasia and restenosis in patients after bare-metal stent implantation, it is not known whether this effect occurs after DES implantation in diabetic patients.

Methods: This randomized, multicenter, prospective study compared triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol, triple group, n = 200) and dual antiplatelet therapy (aspirin and clopidogrel, standard group, n = 200) for 6 months in patients with DM receiving DES. The primary end point was in-stent late loss at 6 months.

Results: The 2 groups had similar baseline clinical and angiographic characteristics. The in-stent (0.25 ± 0.53 mm vs. 0.38 ± 0.54 mm, p = 0.025) and in-segment (0.42 ± 0.50 mm vs. 0.53 ± 0.49 mm, p = 0.031) late loss were significantly lower in the triple versus standard group, as were 6-month in-segment restenosis (8.0% vs. 15.6%, p = 0.033) and 9-month target lesion revascularization (TLR) (2.5% vs. 7.0%, p = 0.034). At 9 months, major adverse cardiac events, including death, myocardial infarction, and TLR, tended to be lower in the triple than in the standard group (3.0% vs. 7.0%, p = 0.066). Multivariate analysis showed that sirolimus-eluting stents and the use of cilostazol were strong predictors of reduced restenosis or TLR.

Conclusions: Triple antiplatelet therapy after DES implantation decreased angiographic restenosis and extent of late loss, resulting in a reduced risk of 9-month TLR compared with dual antiplatelet therapy in diabetic patients.

Abbreviations and Acronyms   BMS = bare-metal stent(s)   DES = drug-eluting stent(s)   MACE = major adverse cardiac events   MI = myocardial infarction   PES = paclitaxel-eluting stent(s)   QCA = quantitative coronary angiography   SES = sirolimus-eluting stent(s)   TLR = target lesion revascularization   TVR = target vessel revascularization

Related Article

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 51: A31-A32. [Full Text] [PDF]

This article has been cited by other articles:

				D. J. Angiolillo, P. Capranzano, S. Goto, M. Aslam, B. Desai, R. K. Charlton, Y. Suzuki, L. C. Box, S. B. Shoemaker, M. M. Zenni, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study Eur. Heart J., June 21, 2008; (2008) ehn287v1. [Abstract] [Full Text] [PDF]